Prediction for Critical Outcomes of Patients With COVID-19

November 17, 2021 updated by: Naichuan Su, Academic Centre for Dentistry in Amsterdam

Development and External Validation of a Prediction Model for Critical Outcomes of Patients With Confirmed COVID-19 in the Hospital Setting Based on Demographic Characteristics, Medical Conditions and Oral Health

The study aims to develop and externally validate a prediction model for the critical outcomes of COVID-19 patients using predictors which can be easily obtained in clinical practice, including patients' demographic characteristics, self-reported medical conditions, and oral health.

Study Overview

Status

Active, not recruiting

Intervention / Treatment

Detailed Description

Background The novel coronavirus disease 2019 (COVID-19) pandemic has presented an important and urgent threat to global health since its outbreak in December 2019. The COVID-19 does not only affect the respiratory tract, but also other organs in human body including lungs, liver, kidney, heart, vessels, and other organs (1). Respiratory failure and acute respiratory distress syndrome (ARDS) are the most common serious complications of COVID-19 infection (2). The crude mortality rates (CMRs) of COVID-19 varies in different locations, which ranges from 37.0/100,000 to 167.6/100,000 in several European countries up to 30th August 2020 (3). The in-hospital mortality of COVID-19 was reported to be 17.1% based on 33 studies from 13,398 patients (4), and it was 2.9 times higher than that of influenza based on the French national administrative database (5). It was reported that 26% of the COVID-19 patients admitted to ICU with severe status and 31% of the patients who admitted to ICU died based on 37 studies from 24,983 patients (6).

There are several risk factors on patients' demographic characteristics and underlying medical conditions which were shown be associated with the critical outcomes of COVID-19 (7). In addition, poor oral health, in particular periodontitis, was also shown to be associated with the critical outcomes of COVID-19 (8). Marouf et al. showed that COVID-19 patients with periodontitis had 8 times higher odds of death and 3.5 times higher odds of ICU admission than those without periodontitis based on a case-control study (9). This may be because periodontal disease could enhance cytokine release via altered microflora, expression of multiple viral receptors, bacterial superinfection, and aspiration of periodontal pathogens (10). The increased production of pro-inflammatory cytokine, which is referred to as cytokine storm, is the foremost cause of the adverse events of COVID-19 (10).

Because of the high contagiousness, high ICU admission rate, and high mortality of COVID-19, it has led to tremendous increases in the demand for hospital beds and shortage of medical equipment. Therefore, there is an urgent need for a pragmatic risk stratification tool that allows the early identification of the COVID-19 patients who are likely to be at highest risk of ICU admission and death (11). This can help clinicians and policymakers make the decisions on the management and optimize resource allocation. A recent review identified multiple prediction models which have been developed for prediction of prognosis of COVID-19 patients (12). Those prediction models varied in their predictors and performance of the models. A large number of prediction models reflected difficulties in their application in the rapid risk stratification for general COVID-19 patients at their first intake in hospitals because some predictors cannot be easily obtained without professional devices or lab tests, such as C reactive protein, peripheral oxygen saturation, and urea level. Many prediction models showed moderate performance in aspects of discrimination and calibration, and no benefit to clinical decision making (12). In addition, the dental variables were not considered the potential predictors in the previously developed models.

Therefore, the aim of the present study is to develop and externally validate a prediction model for the critical outcomes of COVID-19 patients using predictors which can be easily obtained in clinical practice, including patients' demographic characteristics, self-reported medical conditions, and oral health.

Materials and Methods Participants We include hospitalized patients and outpatients from the Isala Hospital (Zwolle, the Netherlands) with confirmed COVID-19 who visited the Department of Oral and Maxillofacial Surgery (OMFS) between March 2020 and May 2021, if they have had a dental panoramic radiograph (OPG), obtained up to a maximum of 5 years until the end of the current study. The patients are used to develop the prediction model (derivation cohort).

We also include the hospitalized patients and outpatients from Noordwest Ziekenhuis (NWZ) (Alkmaar, the Netherlands) with confirmed COVID-19 to externally validate the prediction model (validation cohort).

Potential predictors

The potential predictors include patients' demographic characteristics, self-reported medical conditions, and oral health. All the potential predictors are collected at baseline. The potential predictors are presented below:

Demographic characteristics

  • Gender
  • Age
  • BMI

Medical conditions

  • Smoking
  • Diabetes
  • Hypertension
  • Hypercholesterolemia
  • COPD
  • CVD
  • Chronic kidney disease
  • OSAS

Dental variables (based on OPG)

  • Number of teeth
  • Number of dental implants

Outcome (endpoint) The endpoint of the study is the presence or absence of the critical outcomes of COVID-19 (dichotomized). The course and outcome of the COVID-19 is classified into (1) ambulatory; (2) hospitalized; (3) ICU admission or death based on the WHO Clinical Progression Scale (13). In the study, the critical outcomes are defined as ICU admission or death, while the non-critical outcomes are defined that patients are ambulatory or hospitalized without ICU admission.

Statistical analysis The prediction modes will be developed and externally validated.

References

  1. Wang X, Fang X, Cai Z, et al. Comorbid Chronic Diseases and Acute Organ Injuries Are Strongly Correlated with Disease Severity and Mortality among COVID-19 Patients: A Systemic Review and Meta-Analysis. Research (Wash D C) 2020; 2402961.
  2. SeyedAlinaghi S, Afsahi AM, MohsseniPour M, et al. Late Complications of COVID-19; a Systematic Review of Current Evidence. Arch Acad Emerg Med 2021; 9: e14.
  3. Villani L, McKee M, Cascini F, et al. Comparison of deaths rates for COVID-19 across Europe during the first wave of the COVID-19 pandemic. Front Public Health 2020; 8: 620416.
  4. Macedo A, Gonçalves N, Febra C. COVID-19 fatality rates in hospitalized patients: systematic review and meta-analysis. Ann Epidemiol 2021; 57: 14-21.
  5. Piroth L, Cottenet J, Mariet AS, et al. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. Lancet Respir Med 2021; 9: 251-259.
  6. Abate SM, Ali SA, Mantfardo B, et al. Rate of intensive care unit admission and outcomes among patients with coronavirus: a systematic review and meta-analysis. PLoS One 2020; 15: e0235653.
  7. Kim HJ, Hwang H, Hong H, et al. A systematic review and meta-analysis of regional risk factors for critical outcomes of COVID-19 during early phase of the pandemic. Sci Rep 2021; 11: 9784.
  8. Botros N, Iyer P, Ojcius DM. Is there an association between oral health and severity of COVID-19 complications? Biomed J 2020; 43: 325-327.
  9. Marouf N, Cai W, Said KN, et al. Association between periodontitis and severity of COVID-19 infection: a case-control study. J Clin Periodontol 2021; 48: 483-491.
  10. Sukumar K, Tadepalli A. Nexus between COVID-19 and periodontal disease. J Int Med Res 2021; 49: 3000605211002695.
  11. Knight SR, Ho A, Pius R, et al. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical characterization protocol: development and validation of the 4C mortality score. BMJ 2020; 370: m3339.
  12. Wynants L, Calster BV, Collins GS, et al. Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal. BMJ 2020; 369: m1328.
  13. WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis 2020; 20: e192-e197.

Study Type

Observational

Enrollment (Anticipated)

600

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Alkmaar, Netherlands
        • Noordwest Ziekenhuis (NWZ)
      • Zwolle, Netherlands
        • Isala Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 99 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The patients were diagnosed as COVID-19 from the Isala Hospital (Zwolle, the Netherlands) or from Noordwest Ziekenhuis (NWZ) (Alkmaar, the Netherlands).

Description

Inclusion Criteria:

  • patients who had a diagnosis of COVID-19 in the hospitals who visited the Department of Oral and Maxillofacial Surgery (OMFS) between March 2020 and May 2021, if they have had a dental panoramic radiograph (OPG), obtained up to a maximum of 5 years until the end of the current study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients with confirmed COVID-19 in the hospital setting
No intervention group

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Critical outcomes of COVID-19
Time Frame: March 2020 and May 2021
The critical outcomes include death, and ICU admission
March 2020 and May 2021

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2021

Primary Completion (Anticipated)

December 1, 2021

Study Completion (Anticipated)

December 1, 2022

Study Registration Dates

First Submitted

November 17, 2021

First Submitted That Met QC Criteria

November 17, 2021

First Posted (Actual)

November 18, 2021

Study Record Updates

Last Update Posted (Actual)

November 18, 2021

Last Update Submitted That Met QC Criteria

November 17, 2021

Last Verified

November 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COVID-19

Clinical Trials on No intervention group

3
Subscribe